Nuvation Bio Inc. Files 8-K on Financials
Ticker: NUVB · Form: 8-K · Filed: Nov 6, 2024 · CIK: 1811063
Sentiment: neutral
Topics: financial-condition, operations-update
TL;DR
Nuvation Bio filed an 8-K on Nov 6th, updating financials. Offices in NY, formerly Panacea Acquisition Corp.
AI Summary
Nuvation Bio Inc. filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition. The filing indicates the company's principal executive offices are located at 1500 Broadway, Suite 1401, New York, NY 10036, with a telephone number of (332) 208-6102. Nuvation Bio Inc. was formerly known as Panacea Acquisition Corp. until April 30, 2020.
Why It Matters
This 8-K filing provides an update on Nuvation Bio Inc.'s operational and financial status, which is crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting operational and financial information, not indicating any immediate or significant new risks.
Key Players & Entities
- Nuvation Bio Inc. (company) — Registrant
- November 6, 2024 (date) — Date of earliest event reported
- 1500 Broadway, Suite 1401, New York, NY 10036 (address) — Principal executive offices
- (332) 208-6102 (phone_number) — Registrant's telephone number
- Panacea Acquisition Corp. (company) — Former company name
- April 30, 2020 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Nuvation Bio Inc.'s results of operations and financial condition.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 6, 2024.
Where are Nuvation Bio Inc.'s principal executive offices located?
Nuvation Bio Inc.'s principal executive offices are located at 1500 Broadway, Suite 1401, New York, NY 10036.
What was Nuvation Bio Inc.'s former company name?
Nuvation Bio Inc.'s former company name was Panacea Acquisition Corp.
On what date did the company change its name from Panacea Acquisition Corp.?
The company changed its name from Panacea Acquisition Corp. on April 30, 2020.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-11-06 16:43:03
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value per share NUVB The New Yo
- $11.50 — of Common Stock at an exercise price of $11.50 per share NUVB.WS The New York Stoc
Filing Documents
- d826537d8k.htm (8-K) — 27KB
- d826537dex991.htm (EX-99.1) — 94KB
- g826537g1105105850017.jpg (GRAPHIC) — 4KB
- 0001193125-24-252153.txt ( ) — 291KB
- nuvb-20241106.xsd (EX-101.SCH) — 4KB
- nuvb-20241106_def.xml (EX-101.DEF) — 13KB
- nuvb-20241106_lab.xml (EX-101.LAB) — 22KB
- nuvb-20241106_pre.xml (EX-101.PRE) — 14KB
- d826537d8k_htm.xml (XML) — 6KB
FINANCIAL STATEMENTS AND EXHIBITS
FINANCIAL STATEMENTS AND EXHIBITS (d)Exhibits. Exhibit Number Description 99.1 Press Release of Nuvation Bio Inc. dated November 6, 2024. 104 Cover Page Interactive Data File (embedded within XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 6, 2024 NUVATION BIO INC. By: /s/ Philippe Sauvage Name: Philippe Sauvage Title: Chief Financial Officer 3